For decades, doctors have faced a difficult challenge when treating heart failure. Unlike some tissues in the body, the heart has very little ability to repair itself after serious injury.
When a heart attack cuts off oxygen to part of the heart, many heart muscle cells die permanently. The body replaces these cells with scar tissue, which weakens the heart and reduces its ability to pump blood.
This damage can gradually lead to heart failure, a condition in which the heart cannot deliver enough blood and oxygen to meet the body’s needs.
Patients often experience breathlessness, exhaustion, swelling, and difficulty performing everyday tasks. Although modern medicines and medical devices have improved care, they cannot restore lost heart muscle.
Researchers in Germany have now taken an important step toward solving this problem. In a study published in the New England Journal of Medicine, scientists reported that heart muscle grown in the laboratory was successfully implanted into patients with severe heart failure and showed signs of improving heart function.
The research was led by teams from the University Medical Center Göttingen and the University Hospital of Schleswig-Holstein. Their work is part of a long-term effort to develop regenerative therapies that can rebuild damaged organs rather than simply treat symptoms.
At the center of the new treatment is stem cell technology. Researchers began with induced pluripotent stem cells, a special type of stem cell that can be created from ordinary adult blood cells. These cells can be programmed to develop into many different tissues in the body.
Scientists converted the stem cells into heart muscle cells and connective tissue cells. They then combined these cells with collagen, a natural structural material, to create sheets of living heart tissue. Multiple tissue units were assembled into a larger patch designed to be placed on the outside of the heart.
The patch contains living, beating heart cells. Once attached to the damaged heart, it is intended to form a new layer of muscle that helps strengthen the weakened heart wall. Researchers hoped this additional muscle tissue would support the heart and improve its pumping performance.
The clinical trial enrolled 20 patients with advanced heart failure. Despite receiving standard medical treatment and implanted devices, all participants continued to have severely reduced heart function. Their hearts pumped less than 35% of the blood contained in the left ventricle with each beat, indicating serious impairment.
Researchers first tested different doses to determine the highest amount of tissue that could be safely implanted. They found that a patch containing roughly 800 million heart cells could be used safely. After establishing this dose, they examined how patients responded.
The results were encouraging. Imaging studies showed that damaged regions of the heart wall became thicker after treatment. Researchers also observed improvements in heart pumping ability and patient-reported quality of life. Some participants experienced greater stability and were able to participate more fully in everyday activities.
One patient, Steffen Eyring, joined the study after suffering a severe heart attack that left him with advanced heart failure. Before treatment, his condition had steadily worsened despite multiple therapies. After receiving the heart patch, his heart function improved slightly and became more stable, allowing him to enjoy more active days.
Researchers emphasize that this does not represent a cure for heart failure. Instead, it demonstrates that growing new heart muscle and implanting it into patients is feasible and may provide meaningful benefits.
The achievement is significant because it moves regenerative heart medicine from theory toward clinical reality. Scientists have spent years demonstrating that stem cells can create heart tissue in laboratories. Showing that such tissue can be implanted safely into human patients and produce measurable biological changes is an important advance.
However, caution is still necessary. The study involved a relatively small number of patients, and larger trials are needed to determine how effective the treatment truly is. Researchers must also evaluate long-term safety and determine which patients are most likely to benefit.
The study’s major strength is that it provides the first clinical evidence from a larger group of patients that laboratory-grown heart muscle can help repair damaged human hearts. Its main limitation is the small sample size typical of an early-stage clinical trial.
Despite these limitations, the findings offer new hope for people living with severe heart failure. Future studies involving additional centers in Europe and the United States are already being planned. If successful, this technology could eventually provide a new treatment option for patients who currently face limited choices beyond mechanical heart devices or transplantation.
The study was published in the New England Journal of Medicine.
Source: University Medical Center Göttingen and University Hospital of Schleswig-Holstein.
